(Q38031417)

27 August 2017

title

A new epoprostenol formulation for the treatment of pulmonary arterial hypertension (English)

1 reference

27 August 2017

Amaris Fuentes

1

1 reference

27 August 2017

Aida Coralic

series ordinal

2

1 reference

27 August 2017

Kyle L Dawson

series ordinal

3

1 reference

27 August 2017

language of work or name

1 reference

1 August 2012

1 reference

American Journal of Health-System Pharmacy

27 August 2017

published in

1 reference

27 August 2017

volume

69

1 reference

27 August 2017

issue

16

1 reference

27 August 2017

page(s)

1389-1393

1 reference

ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American Coll

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110687

Treatment of pulmonary arterial hypertension: the role of prostacyclin and prostaglandin analogs

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110687

Treatment of pulmonary arterial hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110687

Updated evidence-based treatment algorithm in pulmonary arterial hypertension.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110687

Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110687

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110687

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110687

Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110687

Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110687

Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110687

A USA-based registry for pulmonary arterial hypertension: 1982-2006.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110687

Rebound pulmonary hypertension and cardiogenic shock after withdrawal of inhaled prostacyclin

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110687

Pharmacotherapy for idiopathic pulmonary arterial hypertension during the past 25 years

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110687

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110687

Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110687

Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110687

31 March 2020

Identifiers

DOI

10.2146/AJHP110687

1 reference

27 August 2017

1 reference